Observational Study of Paclitaxel-Carboplatin Versus Pemetrexed-Carboplatin for Advanced Pulmonary Adenocarcinoma at a Single Centre in Indonesia

    January 2022 in “ eJournal Kedokteran Indonesia ”
    Rianyta Rianyta, Melva Louisa, Elisna Syahruddin, Vivian Soetikno
    TLDR Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.
    This study compared the efficacy, toxicity, and cost of paclitaxel-carboplatin versus pemetrexed-carboplatin in treating pulmonary adenocarcinoma patients with negative EGFR mutation in Indonesia. It involved 42 patients, with 21 in each treatment group. The effectiveness of both regimens was similar, with no significant difference in overall response rate. Common adverse effects included grade 1-2 anaemia, neutropenia, and leukopenia, while grade 3 toxicities were more frequent in the paclitaxel-carboplatin group. Non-hematological toxicities like nausea, vomiting, and hair loss were observed, with peripheral neuropathy more common in the paclitaxel-carboplatin group. The cost analysis showed that the paclitaxel-carboplatin regimen was 50.25% cheaper per patient than the pemetrexed-carboplatin regimen.
    Discuss this study in the Community →